Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 3;10:777. doi: 10.3389/fonc.2020.00777

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Belderbos, Vroman and Aerts.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Overview of current clinically tested cancer vaccines and cellular therapies for MPM An overview of the working mechanism of CRS-207 (A1), Galinpepimut-s (A2), allogeneic tumor lysate loaded moDC therapy (B1), WT1 moDC therapy (B2), MSLN-specific CD28 co-stimulated CAR T-cell therapy (C1A), MSLN-specific 4-1BB co-stimulated CAR T-cell therapy (C1B) and FAP CAR T-cell therapy (C2). The potential enhancements of MSLN-specific CAR T-cell therapy are displayed in C3. IV, intravenous; ID, intradermal; IP, intrapleural; MSLN, mesothelin; moDC, monocyte-derived dendritic cell; MHC, major histocompatibility complex; TCR, T-cell receptor; WT1, Wilms Tumor 1 protein; TAA, tumor-associated antigen; ITAM, Immunoreceptor tyrosine-based activation motif; DNPD-1R, dominant negative PD1 receptor; CCR2, CC chemokine receptor 2; FAP, fibroblast activation protein.